Oppenheimer Raises Humana (HUM) Price Target to $475

Oppenheimer reiterates its Outperform rating for Humana, increasing the price target to $475 on October 9, 2026, a 13.54% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:08 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer raised its price target on Humana Inc. ($HUM) to $475 from $405 on October 9, 2026, and rates the stock "Outperform".

Since the rating, $HUM is down 4.3% after 1 week and down 4.3% to date (from the $431.87 close on Oct 9, 2026).

HUM Humana Inc.

$413.16 +57.38% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer has reiterated its Outperform rating on Humana Inc. with a new price target of $475, up from $405.
Oppenheimer's $475 price target implies 13.54% upside from Humana Inc.'s ($HUM) current $418.36 share price.
The stock recently traded at $418.36, which is below the new target and about 8.4% under its 52-week high of $456.50.
Humana's revenue for the trailing twelve months stands at $145.7 billion, reflecting a year-over-year growth of 26.2%.

Get $HUM trade alerts by text

We text you when insiders, Congress or big funds trade $HUM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Humana Inc. alert may contain errors. Disclosures

Oppenheimer has reiterated its Outperform rating on Humana Inc. (NYSE: HUM) and raised its price target to $475 from $405 on October 9, 2026. This comes as the stock recently traded at $418.36 on October 16, 2026, which is below the new target price. The shares are currently about 8.4% under their 52-week high of $456.50.

Other Institutional Activity in Humana Inc.

Dodge & Cox Inc. trimmed its holdings in Humana by 440,438 shares, ending with 10,940,380 shares worth approximately $4.5 billion. Meanwhile, Blackrock Inc. added 218,270 shares, bringing its total to 10,417,803 shares valued at about $4.3 billion. Vanguard Capital Management LLC slightly increased its stake by 4,703 shares, holding 7,843,620 shares worth around $3.2 billion. Vanguard Portfolio Management LLC also grew its position by 10,455 shares, totaling 5,818,956 shares valued at about $2.4 billion. State Street Corporation added 3,817 shares, ending with 5,457,072 shares worth approximately $2.3 billion.

Humana Inc. Stock Down 2.1%

Humana's shares are currently trading above both their 50-day moving average by 6.5% and their 200-day moving average by 39.3%. However, they remain below the mean price target of $465.13 set by analysts, indicating potential upside. With a recent price of $418.36, the stock is also 11.9% below the average analyst target.

12-month forecast

$HUM price target

Humana Inc. daily closes and this analyst's $475 target. Not advice.

Recent Earnings

Humana reported trailing twelve-month revenue of $145.7 billion and an EPS of $10.88. The company has shown a year-over-year revenue growth of 26.2% and a net margin of 0.9%. The next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Humana Inc.

On February 23, 2026, Officer Sanjay K. Shetty purchased 810 shares of Humana at an average price of $185.20, totaling approximately $150,016. This transaction was not part of a planned sale.

Analysts Set New Price Targets

On October 9, 2026, Baird upgraded Humana to an Outperform rating with a price target of $596, while Barclays maintained an Overweight rating with a target of $582. UBS later maintained a Neutral rating with a target of $495 on October 12, 2026. Oppenheimer's new price target of $475 is also notable, especially given the current consensus among 24 analysts, who recommend a buy with a mean target of $465.13.

About Humana Inc.

Humana Inc. is a healthcare company based in Louisville, KY, that provides medical and specialty insurance products in the United States. It operates primarily in two segments: Insurance and CenterWell. The company's recent performance and analyst ratings underscore its strong position in the healthcare market.

Bottom Line

Investors should keep an eye on Humana's upcoming earnings report on November 6, 2026, as well as any further analyst updates. Oppenheimer's reiteration of the Outperform rating and target increase reflects confidence in the company's growth potential.